Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... , May 28, 2015  Pharmaceutical ... new drugs and tests, and this is ... instruments that can assist them. This according to ... Information said instruments such as mass spectrometry, ... in the identification of drug targets and ...
(Date:5/28/2015)... May 28, 2015 Henry Schein ... provider of health care products and services to ... reminded its customers that the Henry Schein Disaster ... veterinarians who experience operational, logistical or financial issues ... the South Central region of the U.S. The ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3
... , SAN DIEGO, Nov. 24 ... present at the 21st Annual Piper Jaffray Health Care Conference at ... 2009 at 1:00 p.m. Eastern Time. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ... accessible on the Investors page of the Company,s website at ...
... , CINCINNATI, Nov. 23 HealthWarehouse.com, ... today announced its financial results for the third quarter ended ... driven by heavy growth in prescription sales and pharmacy transfers. ... loss for the quarter was $619,114 compared to a net ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3
(Date:5/30/2015)... May 30, 2015 ProIntro Magnify contains 30 ... and animations. Instantly add an elegant opening title to any ... a range of clean design layouts. ProIntro Magnify is created ... is extremely easy to use. Simply drag a preset into ... on-screen-controls and parameters in the Inspector window then watch as ...
(Date:5/30/2015)... Minneapolis, Minnesota (PRWEB) May 30, 2015 ... recently acquired the Disability Income Associate (DIA) designation ... field. The DIA designation is designed for insurance ... seek to further their knowledge and expertise associated ... , Earning the DIA designation is only the ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... San Francisco, CA (PRWEB) May 30, 2015 ... San Francisco, California, is proud to announce their June ... a featured apartment community in San Francisco, Key Housing ... find quality housing in what is one of the ... Francisco is a plum posting, and understandably anyone who ...
(Date:5/30/2015)... 30, 2015 “ Milli the Snail ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... game that engages and educates children. , Interactive mobile games ... all the content and games they are playing are doing ...
Breaking Medicine News(10 mins):Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2
... A new study shows the number of drug-therapy related ... Drug Administration (FDA) nearly tripled between 1998 and 2005. ... Medicine and colleagues reviewed serious and fatal drug events ... consumers, health professionals and drug manufacturers, and found that ...
... greens, grains, olive oil lived 4 years longer, study ... what,s known as a Mediterranean diet -- one loaded ... help Alzheimer,s patients live longer, a new study suggests. ... habits of people diagnosed with early-stage Alzheimer,s. It follows ...
... Spa ... Vacation, OWINGS MILLS, ... Carrie and Charlotte Hoesing of Lacey,Wash., have been voted the winners of ... vacation,at the luxurious AAA-rated, 5-diamond Phoenician Resort, a $1,000,team-total shopping spree and ...
... portionpals(R), the fastest growing,weight loss tool on the ... with no national retail distribution in only its ... strictly from word-of-mouth," says Matt,Zucker, VP of portionpals(R). ... Michigan became our 250,000 customer! "Our goal is ...
... summer holidays, miracle-diet adherents stick to these diets to lose ... Gyms also become overcrowded with people making a final sprint ... and with few benefits for health. In the field of ... gain weight as years pass by, weight loss should be ...
... events, more than doubled between 1998 and 2005 , , ... adverse drug events more than double between 1998 and 2005 ... deaths, a new study found. , "This is the first ... losing ground in drug safety and improving patient safety in ...
Cached Medicine News:Health News:Study shows adverse drug events reported to the FDA have significantly increased 2Health News:Mediterranean Diet May Boost Alzheimer's Survival 2Health News:Mediterranean Diet May Boost Alzheimer's Survival 3Health News:Mediterranean Diet May Boost Alzheimer's Survival 4Health News:Medifast Announces Winners of Mother-Daughter Challenge 2Health News:Medifast Announces Winners of Mother-Daughter Challenge 3Health News:A chocolate cookie a day puts 20 pounds on an energetically-balanced kid in 4 years 2Health News:Injuries, Deaths Tied to Consumer Drugs Rise Sharply 2Health News:Injuries, Deaths Tied to Consumer Drugs Rise Sharply 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: